Sign In
Buy IVA
$4.04
-0.0500 (-1.22%)
At Close: Jun 03, 2026
Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris
08:30am, Tuesday, 02'nd Jun 2026
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company f
Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
01:30am, Tuesday, 02'nd Jun 2026
Daix (France), New York City (New York, United States), le 2 juin 2026 - Inventiva (Euronext Paris et NASDAQ: IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée da
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
01:30am, Tuesday, 02'nd Jun 2026
Daix (France), New York City (New York, United States), June 2, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on
Inventiva Reports 2026 First Quarter Financial Information¹
04:00pm, Tuesday, 26'th May 2026
Daix (France), New York City (New York, United States), May 26, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company f
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
04:00pm, Thursday, 21'st May 2026
Daix (France), New York (United States), May 21, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the
Inventiva's Speculative Upside Through MASH Is Promising
06:22pm, Friday, 15'th May 2026
Inventiva is now essentially a lanifibranor bet. Their prospects hinge on the upcoming Phase 3 NATiV3 readout, which we should get by Q4 2026. In my view, lanifibranor seems relatively differentiated
Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026
02:30am, Wednesday, 13'th May 2026
Daix (France), New York City (New York, Etats-Unis), le 13 mai 2026 - Inventiva (Euronext Paris et NASDAQ: IVA) (« Inventiva » ou la « Société »), société biopharmaceutique au stade clinique s
Inventiva to Present Abstracts at the EASL Congress 2026
02:30am, Wednesday, 13'th May 2026
Daix (France), New York City (New York, United States) , May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical compa
eGain Launches AI Agent IVA to Deliver Accurate, Conversational Customer Service
03:56am, Wednesday, 06'th May 2026
eGain AI Agent IVA replaces rigid dial trees with natural voice conversations, drawing on a governed knowledge base for accurate, on-brand customer service
Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor
04:00pm, Wednesday, 22'nd Apr 2026
Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva's organizational build-out as it advances toward potential commercialization. Axel-Sven Malkome
Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F
04:00pm, Wednesday, 08'th Apr 2026
Daix (France), New York City (New York, United States), April 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the de
Inventiva (NASDAQ:IVA) Shares Gap Down on Disappointing Earnings
01:30am, Wednesday, 01'st Apr 2026
Inventiva S.A. Sponsored ADR (NASDAQ: IVA - Get Free Report)'s share price gapped down prior to trading on Tuesday following a dissappointing earnings announcement. The stock had previously closed at
Inventiva S.A. (IVA) Q4 2025 Earnings Call Transcript
04:22pm, Tuesday, 31'st Mar 2026
Inventiva S.A. (IVA) Q4 2025 Earnings Call Transcript
Inventiva reports 2025 full year results and provides a business update
04:11pm, Monday, 30'th Mar 2026
Daix (France), New York City (New York, United States), March 30, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the dev
